EarlySign touts study of AI for nonsmall cell lung cancer

2020 06 01 18 51 2022 Cancer Lung 400

Artificial intelligence (AI) developer EarlySign reported results from a study published in the American Journal of Respiratory and Critical Care Medicine that showed its machine-learning model was effective for the early diagnosis of nonsmall cell lung cancer (NSCLC).

Based on clinical characteristics and laboratory testing performed nine to 12 months before a clinical diagnosis of cancer, the EarlySign model identified lung cancer with a sensitivity of 40.3% and specificity of 95%, according to the company. A positive test result indicated a thirteenfold elevation in the odds of lung cancer.

The finding suggests the company's AI model has potential to help prevent lung cancer deaths through early detection.

Page 1 of 6
Next Page